Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Plan Numbers Will Not Match Card Sponsor Totals, CMS’ McClellan Predicts

This article was originally published in The Pink Sheet Daily

Executive Summary

Seniors will not be overwhelmed by a high number of plan choices, the agency administrator maintains. CMS has received a large volume of Part D applications, but not all look “complete and serious,” McClellan indicates.

You may also be interested in...



CMS Holds 300 Validated Medicare Rx Formularies As Submission Deadline Nears

The original deadline for Part D formularies was extended until April 22 for the benefit of potential sponsors, not because the agency is falling behind schedule, CMS' Tudor says. Caremark and PacifiCare execs question why the deadline was moved.

CMS Holds 300 Validated Medicare Rx Formularies As Submission Deadline Nears

The original deadline for Part D formularies was extended until April 22 for the benefit of potential sponsors, not because the agency is falling behind schedule, CMS' Tudor says. Caremark and PacifiCare execs question why the deadline was moved.

Low Medicare Part D Enrollment Could Cause Sponsors To “Retrench” – Attorney

Slow enrollment could result in “significant consolidation” within 18 to 24 months, Sonnenschein Nath & Rosenthal partner Fried says during Drug & Device Dialogue audio conference. He also suggests that the large number of applicants seeking to sponsor Part D plans resulted from a defensive business stance by potential sponsors.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel